Maintenance etidronate in the prevention of malignancy-associated hypercalcemia Journal Article


Authors: Schiller, J. H.; Rasmussen, P.; Benson, A. B. 3rd; Witte, R. S.; Bockman, R. S.; Harvey, H. A.; Siris, E. S.; Citrin, D. L.; Greco, F. A.; Stock, J. L.
Article Title: Maintenance etidronate in the prevention of malignancy-associated hypercalcemia
Abstract: Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect. © 1987, American Medical Association. All rights reserved.
Keywords: clinical article; controlled study; middle aged; placebo; diarrhea; drug efficacy; skin toxicity; neoplasms; nausea; recurrence; hypercalcemia; rash; gastrointestinal toxicity; drug therapy; double blind procedure; double-blind method; administration, oral; adverse drug reaction; therapy; clinical trials; hypocalcemia; oral drug administration; random allocation; prevention; intoxication; etidronic acid; patient dropouts; cancer; humans; human; male; female; priority journal
Journal Title: Archives of Internal Medicine
Volume: 147
Issue: 5
ISSN: 0003-9926
Publisher: American Medical Association  
Date Published: 1987-05-01
Start Page: 963
End Page: 966
Language: English
DOI: 10.1001/archinte.1987.00370050155026
PUBMED: 3107487
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard Bockman
    24 Bockman